At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 171 enrolled
Drug / intervention
Ponatinibdrug
Likely dose
Ponatinib 45mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Ponatinib in Cohorts of Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers
In Brief
A Phase 2 clinical trial evaluating Ponatinib for Adenocarcinoma of the Lung and 7 related conditions. Completed, enrolled 171 participants across 1 site.
Detailed Summary
This phase II trial studies how well ponatinib hydrochloride works in treating patients with stage III-IV lung cancer. Ponatinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdenocarcinoma of the Lung, Extensive Stage Small Cell Lung Cancer, Limited Stage Small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Recurrent Small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
CountriesUnited States
CollaboratorsAriad Pharmaceuticals
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedSep 2013
Enrollment StartSep 2013
Primary CompletionJan 2017
Study CompletionNov 2017
TodayJul 2026
First PostedSep 5, 2013
Enrollment StartSep 24, 2013
Primary CompletionJan 1, 2017
Study CompletionNov 1, 2017
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 12.8 years ago
Interventions
Ponatinibdrug
Ponatinib 45mg taken by mouth each day at the same time with or without food